Memantine augmentation for refractory obsessive–compulsive disorder
Glutamatergic hyperactivity hypothesis in obsessive–compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N-methyl- d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive–compulsive disorder treated with an augmentation of memantine at...
Uloženo v:
| Vydáno v: | Progress in neuro-psychopharmacology & biological psychiatry Ročník 30; číslo 6; s. 1173 - 1175 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Amsterdam
Elsevier Inc
30.08.2006
Elsevier |
| Témata: | |
| ISSN: | 0278-5846, 1878-4216 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Glutamatergic hyperactivity hypothesis in obsessive–compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive
N-methyl-
d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive–compulsive disorder treated with an augmentation of memantine at 15 mg/day. The first case did not benefit from such treatment, while the second showed immediate and substantial improvement. Contrasting results, reflecting different subtypes of OCD, are discussed. We hypothesized that in certain OCD subtypes an agent that enhances memory for actions may promote a reduction in orbitofrontal activation. |
|---|---|
| AbstractList | Glutamatergic hyperactivity hypothesis in obsessive–compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive
N-methyl-
d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive–compulsive disorder treated with an augmentation of memantine at 15 mg/day. The first case did not benefit from such treatment, while the second showed immediate and substantial improvement. Contrasting results, reflecting different subtypes of OCD, are discussed. We hypothesized that in certain OCD subtypes an agent that enhances memory for actions may promote a reduction in orbitofrontal activation. Glutamatergic hyperactivity hypothesis in obsessive-compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N- methyl-d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive-compulsive disorder treated with an augmentation of memantine at 15 mg/day. The first case did not benefit from such treatment, while the second showed immediate and substantial improvement. Contrasting results, reflecting different subtypes of OCD, are discussed. We hypothesized that in certain OCD subtypes an agent that enhances memory for actions may promote a reduction in orbitofrontal activation. Glutamatergic hyperactivity hypothesis in obsessive-compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive-compulsive disorder treated with an augmentation of memantine at 15 mg/day. The first case did not benefit from such treatment, while the second showed immediate and substantial improvement. Contrasting results, reflecting different subtypes of OCD, are discussed. We hypothesized that in certain OCD subtypes an agent that enhances memory for actions may promote a reduction in orbitofrontal activation.Glutamatergic hyperactivity hypothesis in obsessive-compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive-compulsive disorder treated with an augmentation of memantine at 15 mg/day. The first case did not benefit from such treatment, while the second showed immediate and substantial improvement. Contrasting results, reflecting different subtypes of OCD, are discussed. We hypothesized that in certain OCD subtypes an agent that enhances memory for actions may promote a reduction in orbitofrontal activation. |
| Author | Biondi, Massimo Pasquini, Massimo |
| Author_xml | – sequence: 1 givenname: Massimo surname: Pasquini fullname: Pasquini, Massimo email: maxpasquini@tiscalinet.it – sequence: 2 givenname: Massimo surname: Biondi fullname: Biondi, Massimo |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17900701$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16730870$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkcFu1DAQQC1URLdbvgAJ5UJvG8ax4ziHHlDVQqUiLvRsOfYEeZXYqZ1U6o1_4A_7JfWyC0g9lJPH0ntzeHNCjnzwSMg7CiUFKj5uy8lP3VRWAKIEXgJlr8iKykZueEXFEVlBledacnFMTlLaAmQE2BtyTEXDQDawIpdfcdR-dh4LvfwY0c96dsEXfYhFxD5qM4f4UIQuYUruHh9__jJhnJZh9ymsSyFajKfkda-HhG8P75rcXl1-v_iyufn2-fri083GcM7mDTfWUNH3mlPaNay20oLt6ppK3vaVQawrUWndYyakZbK2vayaDqXQTdu1mq3J2X7vFMPdgmlWo0sGh0F7DEtSQgqgEth_wQqkzA3qDL4_gEs3olVTdKOOD-pPoQx8OAA6GT3kIt649I9rWoAmd12Tds-ZGFLK6ZRx-5Zz1G5QFNTuamqrfl9N7a6mgKusZpc9c_-uf9E631uYi987jCoZh96gdRHNrGxwL_pPvOez6w |
| CODEN | PNPPD7 |
| CitedBy_id | crossref_primary_10_1111_pcn_13565 crossref_primary_10_1097_YIC_0000000000000314 crossref_primary_10_1097_WNF_0000000000000029 crossref_primary_10_1111_pcn_12394 crossref_primary_10_1016_j_psychres_2021_113853 crossref_primary_10_1016_j_niox_2009_07_001 crossref_primary_10_1016_j_yebeh_2009_06_011 crossref_primary_10_1007_s00213_012_2904_9 crossref_primary_10_1176_foc_9_3_foc299 crossref_primary_10_3389_fped_2014_00087 crossref_primary_10_1016_j_pnpbp_2008_01_008 crossref_primary_10_2147_JEP_S255375 crossref_primary_10_1016_j_biomed_2012_04_003 crossref_primary_10_1517_14656566_8_5_563 crossref_primary_10_1517_14728214_2014_875157 crossref_primary_10_1016_j_psc_2014_05_006 crossref_primary_10_1002_da_22103 crossref_primary_10_1016_j_jveb_2008_10_008 crossref_primary_10_1111_j_1742_1241_2007_01356_x crossref_primary_10_1016_j_jpsychires_2024_03_044 crossref_primary_10_1016_j_physbeh_2019_01_013 crossref_primary_10_1517_14740330802528420 crossref_primary_10_1016_j_drudis_2007_12_009 crossref_primary_10_1016_j_pharmthera_2011_09_006 crossref_primary_10_1097_JCP_0b013e3181727548 crossref_primary_10_1177_0004867412461958 crossref_primary_10_1186_s13063_016_1266_8 crossref_primary_10_1080_15622970802465807 crossref_primary_10_1177_104012371803000307 crossref_primary_10_1007_s11055_009_9244_1 crossref_primary_10_1016_j_jpsychires_2018_07_008 crossref_primary_10_1080_14656566_2018_1528230 crossref_primary_10_7759_cureus_37833 crossref_primary_10_1038_tp_2013_35 crossref_primary_10_1097_JCP_0b013e3181c856de crossref_primary_10_1176_foc_5_3_foc299 crossref_primary_10_3390_biom11071007 crossref_primary_10_1016_j_pbb_2011_10_007 crossref_primary_10_1017_S1461145711001829 crossref_primary_10_1080_17460441_2024_2387127 crossref_primary_10_1016_j_pbb_2011_04_010 crossref_primary_10_1016_j_ejphar_2008_01_035 crossref_primary_10_1002_da_20769 crossref_primary_10_2165_11632860_000000000_00000 crossref_primary_10_1016_j_jpsychires_2008_10_007 crossref_primary_10_2174_0929867324666171108152035 crossref_primary_10_2165_11634390_000000000_00000 crossref_primary_10_4103_0019_5545_192001 crossref_primary_10_1111_nyas_12318 crossref_primary_10_1016_j_comppsych_2022_152352 crossref_primary_10_1002_eat_20541 crossref_primary_10_1016_j_jpsychires_2012_09_015 crossref_primary_10_1089_cap_2015_0073 crossref_primary_10_1176_appi_ajp_2008_08091427 crossref_primary_10_1097_JCP_0b013e318192e9a4 crossref_primary_10_1016_j_jocrd_2012_10_003 crossref_primary_10_1038_s41398_018_0162_2 crossref_primary_10_1097_JCP_0b013e3181c8b44f |
| Cites_doi | 10.1176/appi.ajp.162.11.2191-a 10.1016/j.pnpbp.2004.06.014 10.1016/S0896-6273(02)00625-6 10.1016/S0005-7967(99)00049-2 10.1016/S0278-5846(00)00146-9 10.1159/000049292 10.1254/jjp.88.133 10.1080/10673220303949 10.1176/appi.ajp.163.1.153 10.1016/j.pnpbp.2004.08.011 10.1016/S0005-7967(00)00064-4 10.1016/S0005-7967(98)00075-8 10.1016/S0028-3908(00)00145-3 10.1016/S0006-3223(98)00099-7 10.1124/jpet.104.077172 |
| ContentType | Journal Article |
| Copyright | 2006 Elsevier Inc. 2006 INIST-CNRS |
| Copyright_xml | – notice: 2006 Elsevier Inc. – notice: 2006 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TK 7X8 |
| DOI | 10.1016/j.pnpbp.2006.04.013 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | Neurosciences Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1878-4216 |
| EndPage | 1175 |
| ExternalDocumentID | 16730870 17900701 10_1016_j_pnpbp_2006_04_013 S0278584606001758 |
| Genre | Journal Article Case Reports |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AADPK AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXLA AAXUO ABCQJ ABFRF ABIVO ABJNI ABMAC ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMQ HMT HVGLF HZ~ IHE J1W KOM L7B M2V M34 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SES SEW SNS SPT SSN SSP SSZ T5K TEORI WUQ ZGI ~G- 9DU AATTM AAXKI AAYWO AAYXX ABWVN ACLOT ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD BNPGV IQODW SSH CGR CUY CVF ECM EIF NPM 7TK 7X8 |
| ID | FETCH-LOGICAL-c443t-4cdc16ffa411b735d8d0db551849f2cee5262aafefa48d385df827be86a79b9a3 |
| ISICitedReferencesCount | 79 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000239008600033&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0278-5846 |
| IngestDate | Thu Oct 02 18:36:55 EDT 2025 Sat Sep 27 20:17:11 EDT 2025 Wed Feb 19 01:53:08 EST 2025 Wed Apr 02 07:23:55 EDT 2025 Sat Nov 29 03:06:51 EST 2025 Tue Nov 18 22:33:37 EST 2025 Fri Feb 23 02:32:22 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Obsessive–compulsive disorder Memantine Glutamatergic transmission Memory for actions Obsessive compulsive disorder Memory Anxiety disorder Glutamate receptor Antialzheimer agent Antiparkinson agent Amantadine dérivatives Obsessive-compulsive disorder Antagonist NMDA receptor |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c443t-4cdc16ffa411b735d8d0db551849f2cee5262aafefa48d385df827be86a79b9a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Case Study-2 ObjectType-Feature-4 ObjectType-Report-1 ObjectType-Article-3 |
| PMID | 16730870 |
| PQID | 20886735 |
| PQPubID | 23462 |
| PageCount | 3 |
| ParticipantIDs | proquest_miscellaneous_68601803 proquest_miscellaneous_20886735 pubmed_primary_16730870 pascalfrancis_primary_17900701 crossref_citationtrail_10_1016_j_pnpbp_2006_04_013 crossref_primary_10_1016_j_pnpbp_2006_04_013 elsevier_sciencedirect_doi_10_1016_j_pnpbp_2006_04_013 |
| PublicationCentury | 2000 |
| PublicationDate | 2006-08-30 |
| PublicationDateYYYYMMDD | 2006-08-30 |
| PublicationDate_xml | – month: 08 year: 2006 text: 2006-08-30 day: 30 |
| PublicationDecade | 2000 |
| PublicationPlace | Amsterdam |
| PublicationPlace_xml | – name: Amsterdam – name: England |
| PublicationTitle | Progress in neuro-psychopharmacology & biological psychiatry |
| PublicationTitleAlternate | Prog Neuropsychopharmacol Biol Psychiatry |
| PublicationYear | 2006 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Poyurovsky, Weizman, Weizman, Koran (bib12) 2005; 162 Zitterl, Urban, Linzmayer, Aigner, Demal, Semler (bib17) 2001; 34 Pasquini, Garavini, Biondi (bib10) 2005; 29 Araki, Suemaru, Gomita (bib2) 2002; 88 Mansvelder, Keath, McGehee (bib9) 2002; 33 Kumar (bib6) 2004; 52 Lundberg, Carlsson, Norfeldt, Carlsson (bib8) 2004; 28 Tallis, Pratt, Jamani (bib14) 1999; 37 Girod, Barazangi, McGehhe, Role (bib4) 2000; 39 Kuipers, Trentani, ter Horst, den Boer (bib5) 2005 Salkovskis (bib13) 1999; 37 S Zarate, Singh, Quiroz, De Jesus, Denicoff, Luckenbaugh (bib16) 2006; 163 Aracava, Pereira, Maelicke, Albuquerque (bib1) 2005; 312 Lochner, Stein (bib7) 2003; 11 Pujol, Torres, Deus, Cardoner, Pifarre, Capdevila (bib11) 1999; 45 Tolin, Abramowitz, Brigidi, Amir, Street, Foa (bib15) 2001; 39 Carlsson (bib3) 2001; 25 Araki (10.1016/j.pnpbp.2006.04.013_bib2) 2002; 88 Girod (10.1016/j.pnpbp.2006.04.013_bib4) 2000; 39 Tallis (10.1016/j.pnpbp.2006.04.013_bib14) 1999; 37 Zitterl (10.1016/j.pnpbp.2006.04.013_bib17) 2001; 34 Salkovskis (10.1016/j.pnpbp.2006.04.013_bib13) 1999; 37 S Kumar (10.1016/j.pnpbp.2006.04.013_bib6) 2004; 52 Pasquini (10.1016/j.pnpbp.2006.04.013_bib10) 2005; 29 Aracava (10.1016/j.pnpbp.2006.04.013_bib1) 2005; 312 Mansvelder (10.1016/j.pnpbp.2006.04.013_bib9) 2002; 33 Poyurovsky (10.1016/j.pnpbp.2006.04.013_bib12) 2005; 162 Lundberg (10.1016/j.pnpbp.2006.04.013_bib8) 2004; 28 Zarate (10.1016/j.pnpbp.2006.04.013_bib16) 2006; 163 Pujol (10.1016/j.pnpbp.2006.04.013_bib11) 1999; 45 Tolin (10.1016/j.pnpbp.2006.04.013_bib15) 2001; 39 Kuipers (10.1016/j.pnpbp.2006.04.013_bib5) 2005 Carlsson (10.1016/j.pnpbp.2006.04.013_bib3) 2001; 25 Lochner (10.1016/j.pnpbp.2006.04.013_bib7) 2003; 11 |
| References_xml | – volume: 37 S start-page: 29 year: 1999 end-page: 52 ident: bib13 article-title: Understanding and treating obsessive–compulsive disorder publication-title: Behav Res Ther – volume: 163 start-page: 153 year: 2006 end-page: 155 ident: bib16 article-title: A double-blind, placebo-controlled study of memantine in the treatment of major depression publication-title: Am J Psychiatry – volume: 33 start-page: 905 year: 2002 end-page: 919 ident: bib9 article-title: Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas publication-title: Neuron – volume: 162 start-page: 2191 year: 2005 end-page: 2192 ident: bib12 article-title: Memantine for treatment-resistant OCD publication-title: Am J Psychiatry – year: 2005 ident: bib5 article-title: Looking beyond the receptors: molecular biological approaches to antidepressant therapy publication-title: Current and future developments in psychopharmacology – volume: 312 start-page: 1195 year: 2005 end-page: 1205 ident: bib1 article-title: Memantine blocks alpha 7* nicotinic acetylcholine receptors more potently than NMDA receptors in rat hippocampal neurons publication-title: J Pharmacol Exp Ther – volume: 39 start-page: 2715 year: 2000 end-page: 2725 ident: bib4 article-title: Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors publication-title: Neuropharmacology – volume: 88 start-page: 133 year: 2002 end-page: 138 ident: bib2 article-title: Neuronal nicotinic receptor and psychiatric disorders: functional and behavioural effects of nicotine publication-title: Jpn J Pharmacol – volume: 25 start-page: 5 year: 2001 end-page: 26 ident: bib3 article-title: On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive–compulsive disorder and attention-deficit hyperactivity disorder publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry – volume: 37 start-page: 161 year: 1999 end-page: 166 ident: bib14 article-title: Obsessive compulsive disorder, checking, and non-verbal memory: a neuropsychological investigation publication-title: Behav Res Ther – volume: 34 start-page: 113 year: 2001 end-page: 117 ident: bib17 article-title: Memory deficits in patients with DSM-IV obsessive–compulsive disorder publication-title: Psychopathology – volume: 52 start-page: 307 year: 2004 end-page: 309 ident: bib6 article-title: Memantine: pharmacological properties and clinical uses publication-title: Neurol India – volume: 39 start-page: 913 year: 2001 end-page: 927 ident: bib15 article-title: Memory and memory confidence in obsessive–compulsive disorder publication-title: Behav Res Ther – volume: 28 start-page: 1195 year: 2004 end-page: 1199 ident: bib8 article-title: Nicotine treatment of obsessive–compulsive disorder publication-title: Prog Neuropsychopharmacol Biol Psychiatry Nov – volume: 45 start-page: 891 year: 1999 end-page: 897 ident: bib11 article-title: Functional magnetic resonance imaging study of frontal lobe activation during word generation in obsessive–compulsive disorder publication-title: Biol Psychiatry – volume: 11 start-page: 113 year: 2003 end-page: 132 ident: bib7 article-title: Heterogeneity of obsessive–compulsive disorder: a literature review publication-title: Harv Rev Psychiatry – volume: 29 start-page: 157 year: 2005 end-page: 159 ident: bib10 article-title: Nicotine augmentation for refractory obsessive–compulsive disorder. A case report publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry – volume: 162 start-page: 2191 year: 2005 ident: 10.1016/j.pnpbp.2006.04.013_bib12 article-title: Memantine for treatment-resistant OCD publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.162.11.2191-a – volume: 28 start-page: 1195 issue: 7 year: 2004 ident: 10.1016/j.pnpbp.2006.04.013_bib8 article-title: Nicotine treatment of obsessive–compulsive disorder publication-title: Prog Neuropsychopharmacol Biol Psychiatry Nov doi: 10.1016/j.pnpbp.2004.06.014 – volume: 33 start-page: 905 year: 2002 ident: 10.1016/j.pnpbp.2006.04.013_bib9 article-title: Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas publication-title: Neuron doi: 10.1016/S0896-6273(02)00625-6 – volume: 52 start-page: 307 year: 2004 ident: 10.1016/j.pnpbp.2006.04.013_bib6 article-title: Memantine: pharmacological properties and clinical uses publication-title: Neurol India – volume: 37 S start-page: 29 issue: 1 year: 1999 ident: 10.1016/j.pnpbp.2006.04.013_bib13 article-title: Understanding and treating obsessive–compulsive disorder publication-title: Behav Res Ther doi: 10.1016/S0005-7967(99)00049-2 – volume: 25 start-page: 5 issue: 1 year: 2001 ident: 10.1016/j.pnpbp.2006.04.013_bib3 article-title: On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive–compulsive disorder and attention-deficit hyperactivity disorder publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry doi: 10.1016/S0278-5846(00)00146-9 – volume: 34 start-page: 113 year: 2001 ident: 10.1016/j.pnpbp.2006.04.013_bib17 article-title: Memory deficits in patients with DSM-IV obsessive–compulsive disorder publication-title: Psychopathology doi: 10.1159/000049292 – volume: 88 start-page: 133 year: 2002 ident: 10.1016/j.pnpbp.2006.04.013_bib2 article-title: Neuronal nicotinic receptor and psychiatric disorders: functional and behavioural effects of nicotine publication-title: Jpn J Pharmacol doi: 10.1254/jjp.88.133 – year: 2005 ident: 10.1016/j.pnpbp.2006.04.013_bib5 article-title: Looking beyond the receptors: molecular biological approaches to antidepressant therapy – volume: 11 start-page: 113 year: 2003 ident: 10.1016/j.pnpbp.2006.04.013_bib7 article-title: Heterogeneity of obsessive–compulsive disorder: a literature review publication-title: Harv Rev Psychiatry doi: 10.1080/10673220303949 – volume: 163 start-page: 153 year: 2006 ident: 10.1016/j.pnpbp.2006.04.013_bib16 article-title: A double-blind, placebo-controlled study of memantine in the treatment of major depression publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.163.1.153 – volume: 29 start-page: 157 year: 2005 ident: 10.1016/j.pnpbp.2006.04.013_bib10 article-title: Nicotine augmentation for refractory obsessive–compulsive disorder. A case report publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2004.08.011 – volume: 39 start-page: 913 issue: 8 year: 2001 ident: 10.1016/j.pnpbp.2006.04.013_bib15 article-title: Memory and memory confidence in obsessive–compulsive disorder publication-title: Behav Res Ther doi: 10.1016/S0005-7967(00)00064-4 – volume: 37 start-page: 161 issue: 2 year: 1999 ident: 10.1016/j.pnpbp.2006.04.013_bib14 article-title: Obsessive compulsive disorder, checking, and non-verbal memory: a neuropsychological investigation publication-title: Behav Res Ther doi: 10.1016/S0005-7967(98)00075-8 – volume: 39 start-page: 2715 year: 2000 ident: 10.1016/j.pnpbp.2006.04.013_bib4 article-title: Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors publication-title: Neuropharmacology doi: 10.1016/S0028-3908(00)00145-3 – volume: 45 start-page: 891 year: 1999 ident: 10.1016/j.pnpbp.2006.04.013_bib11 article-title: Functional magnetic resonance imaging study of frontal lobe activation during word generation in obsessive–compulsive disorder publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(98)00099-7 – volume: 312 start-page: 1195 issue: 3 year: 2005 ident: 10.1016/j.pnpbp.2006.04.013_bib1 article-title: Memantine blocks alpha 7* nicotinic acetylcholine receptors more potently than NMDA receptors in rat hippocampal neurons publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.104.077172 |
| SSID | ssj0001303 |
| Score | 2.1143205 |
| Snippet | Glutamatergic hyperactivity hypothesis in obsessive–compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive
N-methyl-... Glutamatergic hyperactivity hypothesis in obsessive-compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive... Glutamatergic hyperactivity hypothesis in obsessive-compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N-... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1173 |
| SubjectTerms | Adult Adult and adolescent clinical studies Anxiety disorders. Neuroses Biological and medical sciences Drug Resistance Drug Therapy, Combination Excitatory Amino Acid Antagonists - therapeutic use Female Glutamatergic transmission Humans Male Medical sciences Memantine Memantine - therapeutic use Memory for actions Middle Aged Neuropharmacology Obsessive-Compulsive Disorder - drug therapy Obsessive-Compulsive Disorder - psychology Obsessive-compulsive disorders Obsessive–compulsive disorder Pharmacology. Drug treatments Psychiatric Status Rating Scales Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Serotonin Uptake Inhibitors - therapeutic use |
| Title | Memantine augmentation for refractory obsessive–compulsive disorder |
| URI | https://dx.doi.org/10.1016/j.pnpbp.2006.04.013 https://www.ncbi.nlm.nih.gov/pubmed/16730870 https://www.proquest.com/docview/20886735 https://www.proquest.com/docview/68601803 |
| Volume | 30 |
| WOSCitedRecordID | wos000239008600033&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1878-4216 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001303 issn: 0278-5846 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF7RlgMSQrxJgeAD7SVx5bU33vWxKokAtSEHV_LN2rW9KFXruHFStf-e2YfjlDYFDlysyNmH4m8yM56Z_QahzxgUHsmp5wrGpUuIJC4nVLpewAshMMzCXDeboOMxS5JoYkPZtW4nQMuSXV9H1X-FGu4B2Oro7D_AvVoUbsBnAB2uADtc_wr4k-KCq_YPRY8vf17Yo0WmnBCs4Vz317npzYRK9oKqc1VR-fJcV7Hnlopz3WOdqAIupQ6nZU-TX7rm4FbVcl6bohtD56Qxv11CbTJU9eVyqttH9U7AXwcJacPzszK_88VaIII1ORWjr3yqDnHZiKJVru2A3zQlxqaFibW6ijH0Xo1uggtnB1VZicomj8iBh4PWgDVJ-_GPdHR6fJzGwyTeC0bVpauai6kk_F7wxQC9hXZ8OohA_e0cfhsm31dGW5lyHY6zv6EhqNKlgHf23uTEPK14DY9Zmp4om19atPMSP0fP7FuHc2ik5QV6VJQv0f7EQHjTd-L2FF7dd_adyRq4r9DRSqScdZFyQKScVqSc-0TKaUTqNTodDeOjr65tvuFmhAQLl2R5hkMpOcFY0GCQs9zLheLvI5H0wbUa-KHPuSxgBMsDNsgl86koWMhpJCIevEHb5aws3iFHeOD1R4SEEguS-QNOaRF4UmY-pTm4Qx3kN08zzSwzvWqQcp42JYhnqYZA9UwNU4-kAEEH9VeTKkPM8vDwsIEptb6l8RlTELSHJ3ZvgdpuRiPFlYU76FODcgqqWeXbeFnMljWswlgIj27ziJCFikAPNnlrxKNdHSZ6YEt3_7j6e_Sk_Td-QNuL-bL4iB5nV4tpPe-iLZqwrpX2X_Hlyyg |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Memantine+augmentation+for+refractory+obsessive-compulsive+disorder&rft.jtitle=Progress+in+neuro-psychopharmacology+%26+biological+psychiatry&rft.au=Pasquini%2C+Massimo&rft.au=Biondi%2C+Massimo&rft.date=2006-08-30&rft.issn=0278-5846&rft.volume=30&rft.issue=6&rft.spage=1173&rft.epage=1175&rft_id=info:doi/10.1016%2Fj.pnpbp.2006.04.013&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0278-5846&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0278-5846&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0278-5846&client=summon |